mCRPC
Akeega Plus Prednisone Approved for BRCA-mutated mCRPC
The FDA approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), ...
AUGUST 16, 2023
Continuing Enzalutamide After Progression and Adding Docetaxel Improved PFS in mCRPC, Study Shows
Adding docetaxel and prednisolone after progression on enzalutamide (Xtandi, Astellas) alone significantly extended ...
MARCH 25, 2022
Targeted Radioligand Therapy Approved to Treat Advanced Prostate Cancer
The FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis), a targeted radioligand therapy, for ...
MARCH 25, 2022
Lynparza Approved for Use in HRR-Mutated mCRPC
The FDA approved olaparib (Lynparza, AstraZeneca) for the treatment of adults with deleterious or suspected ...
MAY 28, 2020
Rubraca Gains Approval for Use in BRCA-Mutated mCRPC
The FDA granted accelerated approval to rucaparib (Rubraca, Clovis Oncology) for patients with deleterious BRCA ...
MAY 20, 2020
